Ornithine decarboxylase (ODC1), a critical regulatory enzyme in polyamine biosynthesis, is a direct transcriptional target of MYCN, amplification of which is a powerful marker of aggressive neuroblastoma. A single nucleotide polymorphism (SNP), G316A, within the first intron of ODC1, results in genotypes wildtype GG, and variants AG/AA. CRISPR‐cas9 technology was used to investigate the effects of AG clones from wildtype MYCN‐amplified SK‐N‐BE(2)‐C cells and the effect of the SNP on MYCN binding, and promoter activity was investigated using EMSA and luciferase assays. AG clones exhibited decreased ODC1 expression, growth rates, and histone acetylation and increased sensitivity to ODC1 inhibition. MYCN was a stronger transcriptional regulator of the ODC1 promoter containing the G allele, and preferentially bound the G allele over the A. Two neu-roblastoma cohorts were used to investigate the clinical impact of the SNP. In the study cohort, the minor AA genotype was associated with improved survival, while poor prognosis was associated with the GG genotype and AG/GG genotypes in MYCN‐amplified and non‐amplified patients, re-spectively. These effects were lost in the GWAS cohort. We have demonstrated that the ODC1 G316A polymorphism has functional significance in neuroblastoma and is subject to allele‐specific regulation by the MYCN oncoprotein.

A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma / Gamble L.D.; Purgato S.; Henderson M.J.; Di Giacomo S.; Russell A.J.; Pigini P.; Murray J.; Valli E.; Milazzo G.; Giorgi F.M.; Cowley M.; Ashton L.J.; Bhalshankar J.; Schleiermacher G.; Rihani A.; Van Maerken T.; Vandesompele J.; Speleman F.; Versteeg R.; Koster J.; Eggert A.; Noguera R.; Stallings R.L.; Tonini G.P.; Fong K.; Vaksman Z.; Diskin S.J.; Maris J.M.; London W.B.; Marshall G.M.; Ziegler D.S.; Hogarty M.D.; Perini G.; Norris M.D.; Haber M.. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 13:8(2021), pp. 1807.1807-1807.1825. [10.3390/cancers13081807]

A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma

Purgato S.;Di Giacomo S.;Pigini P.;Valli E.;Milazzo G.;Giorgi F. M.;Perini G.
;
2021

Abstract

Ornithine decarboxylase (ODC1), a critical regulatory enzyme in polyamine biosynthesis, is a direct transcriptional target of MYCN, amplification of which is a powerful marker of aggressive neuroblastoma. A single nucleotide polymorphism (SNP), G316A, within the first intron of ODC1, results in genotypes wildtype GG, and variants AG/AA. CRISPR‐cas9 technology was used to investigate the effects of AG clones from wildtype MYCN‐amplified SK‐N‐BE(2)‐C cells and the effect of the SNP on MYCN binding, and promoter activity was investigated using EMSA and luciferase assays. AG clones exhibited decreased ODC1 expression, growth rates, and histone acetylation and increased sensitivity to ODC1 inhibition. MYCN was a stronger transcriptional regulator of the ODC1 promoter containing the G allele, and preferentially bound the G allele over the A. Two neu-roblastoma cohorts were used to investigate the clinical impact of the SNP. In the study cohort, the minor AA genotype was associated with improved survival, while poor prognosis was associated with the GG genotype and AG/GG genotypes in MYCN‐amplified and non‐amplified patients, re-spectively. These effects were lost in the GWAS cohort. We have demonstrated that the ODC1 G316A polymorphism has functional significance in neuroblastoma and is subject to allele‐specific regulation by the MYCN oncoprotein.
2021
A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma / Gamble L.D.; Purgato S.; Henderson M.J.; Di Giacomo S.; Russell A.J.; Pigini P.; Murray J.; Valli E.; Milazzo G.; Giorgi F.M.; Cowley M.; Ashton L.J.; Bhalshankar J.; Schleiermacher G.; Rihani A.; Van Maerken T.; Vandesompele J.; Speleman F.; Versteeg R.; Koster J.; Eggert A.; Noguera R.; Stallings R.L.; Tonini G.P.; Fong K.; Vaksman Z.; Diskin S.J.; Maris J.M.; London W.B.; Marshall G.M.; Ziegler D.S.; Hogarty M.D.; Perini G.; Norris M.D.; Haber M.. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 13:8(2021), pp. 1807.1807-1807.1825. [10.3390/cancers13081807]
Gamble L.D.; Purgato S.; Henderson M.J.; Di Giacomo S.; Russell A.J.; Pigini P.; Murray J.; Valli E.; Milazzo G.; Giorgi F.M.; Cowley M.; Ashton L.J.; Bhalshankar J.; Schleiermacher G.; Rihani A.; Van Maerken T.; Vandesompele J.; Speleman F.; Versteeg R.; Koster J.; Eggert A.; Noguera R.; Stallings R.L.; Tonini G.P.; Fong K.; Vaksman Z.; Diskin S.J.; Maris J.M.; London W.B.; Marshall G.M.; Ziegler D.S.; Hogarty M.D.; Perini G.; Norris M.D.; Haber M.
File in questo prodotto:
File Dimensione Formato  
cancers-13-01807-v2.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 2.05 MB
Formato Adobe PDF
2.05 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/831832
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact